Cheaper Nivolumab Biosimilars Boost Cancer Therapy Access in India
Cheaper nivolumab biosimilars are increasing access to cancer immunotherapy in India. A Mumbai oncologist reported a more than 50% rise in prescriptions over six months. Prices have dropped from over Rs 1 lakh to around Rs 30,000 per treatment cycle. However, hospital stocking practices may affect whether patients benefit from these lower costs.
Economic Times··Mumbai